Eli Lilly

LLY Mega Cap

Healthcare · Drug Manufacturers - General

Updated: Apr 5, 2026, 00:03 UTC

$935.58

-1.98% today

52W: $623.78 – $1,133.95

52W Low: $623.78 Position: 61.1% 52W High: $1,133.95

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

40.82x

Price-to-Earnings

Forward P/E

22.24x

Forward Price/Earnings

P/S Ratio

12.85x

Price-to-Sales

EV/EBITDA

27.53x

Enterprise Value/EBITDA

Div. Yield

67%

Annual dividend yield

Market Cap

$837.4B

Market Capitalization

Revenue Growth

42.6%

YoY Revenue Growth

Profit Margin

31.67%

Net profit margin

ROE

101.16%

Return on Equity

Beta

0.5

Market sensitivity

Short Interest

0.86%

% of float sold short

Avg. Volume

3,229,567

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

29 analysts

Avg. Price Target

$1,209.21

+29.25% upside

Target Range

$850.00 – $1,500.00

🚫 Not currently held by any of our 15 tracked Smart Money managers. View Smart Money Tracker →

About the Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocyti

Sector: Healthcare Industry: Drug Manufacturers - General Country: United States Employees: 50,000 Exchange: NYQ